Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles-Reference-Cited by-同舟云学术

Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles

Published:2022-11 Issue:11 Volume:142 Page:3030-3040.e5
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Vergani Elisabetta^ORCID,Busico Adele^ORCID,Dugo Matteo^ORCID,Devecchi Andrea^ORCID,Valeri Barbara^ORCID,Cossa Mara^ORCID,Di Guardo Lorenza^ORCID,De Cecco Loris^ORCID,Feltrin Erika^ORCID,Valle Giorgio^ORCID,Deho Paola^ORCID,Frigerio Simona^ORCID,Lalli Luca^ORCID,Gallino Gianfrancesco^ORCID,Del Vecchio Michele^ORCID,Santinami Mario^ORCID,Pruneri Giancarlo^ORCID,Tamborini Elena^ORCID,Rivoltini Licia^ORCID,Sensi Marialuisa^ORCID,Vallacchi Viviana^ORCID,Rodolfo Monica^ORCID

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference54 articles.

1. Signatures of mutational processes in human cancer;Alexandrov;Nature,2013

2. Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling;Appenzeller-Herzog;Trends Cell Biol,2012

3. Phenotype plasticity as enabler of melanoma progression and therapy resistance;Arozarena;Nat Rev Cancer,2019

4. Comprehensive characterization of cancer driver genes and mutations;Bailey;Cell,2018

5. Genomic classification of cutaneous melanoma;Cancer Genome Atlas Network;Cell,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determinants of resistance and response to melanoma therapy;Nature Cancer;2024-07-17

2. Alterations in Plasma Lipid Profiles Associated with Melanoma and Therapy Resistance;International Journal of Molecular Sciences;2024-01-26

3. Multistep tumor genetic evolution and changes in immunogenicity trigger immune-mediated disease eradication in stage IV melanoma: lessons from a single case;Journal for ImmunoTherapy of Cancer;2024-01

4. Pro-Apoptotic Activity of MCL-1 Inhibitor in Trametinib-Resistant Melanoma Cells Depends on Their Phenotypes and Is Modulated by Reversible Alterations Induced by Trametinib Withdrawal;Cancers;2023-09-29

5. Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells;Frontiers in Oncology;2023-09-18